The obesity drug ‘Wegovy’ can now be prescribed in tertiary hospitals in Korea.

According to industry sources, Novo Nordisk Korea's Wegovy (semaglutide) has passed the drug committees (DCs) of Korrea’s “Big 5 medical institutions,” including Samsung Medical Center, Seoul National University Hospital, and Sinchon Severance Hospital.

Wegovy was approved by the U.S. Food and Drug Administration (FDA) in June 2021 and was granted marketing authorization in Korea in October last year.

The once-weekly obesity treatment is approved as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in a